JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Molecular Surrogate Subtypes of Ovarian and Peritoneal Low-grade Serous Carcinoma

  • 0Department of Pathology and Laboratory Medicine, University of Calgary, Calgary.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists +

|

June 24, 2024

|

June 24, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Low-grade serous carcinoma (LGSC) survival differs between ovarian and peritoneal sites. CDKN2A and PR status may help classify indeterminate implants, but molecular subtyping needs further study.

Area Of Science

  • Gynecologic Oncology
  • Molecular Pathology
  • Cancer Genomics

Background

  • Low-grade serous carcinoma (LGSC) is a rare ovarian cancer subtype (~3% of cases).
  • Peritoneal LGSC (pLGSC) generally shows longer survival than ovarian LGSC (oLGSC).
  • Key molecular alterations include CDKN2A/PR loss, MAPK pathway changes, and USP9X loss.

Purpose Of The Study

  • To investigate molecular subtyping of LGSC using a hierarchical decision tree.
  • To identify clinically applicable molecular subtypes for improved patient stratification.
  • To explore the prognostic value of specific molecular alterations in LGSC.

Main Methods

  • Analysis of 71 LGSC cases.
  • Immunohistochemistry for CDKN2A, ER, PR, NF1, and USP9X.
  • Sequencing for KRAS, NRAS, and BRAF mutations.

Main Results

  • Co-occurrence of key molecular alterations was observed.
  • Hierarchical molecular subtyping did not significantly stratify patients by survival.
  • Confirmed longer survival for pLGSC compared to high-stage oLGSC.
  • Normal CDKN2A and PR status correlated with excellent survival in pLGSC.

Conclusions

  • CDKN2A and PR status may assist in classifying indeterminate implants, distinguishing pLGSC from noninvasive implants.
  • Further evaluation of molecular subtypes in larger cohorts is warranted for prognostic and predictive value.